Page 2 - Satish Waman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Satish waman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Satish Waman Today - Breaking & Trending Today

Supriya Lifescience IPO to open on December 16; plans to raise Rs 700 crore

Supriya Lifescience Limited, a manufacturer of active pharmaceutical ingredients, has fixed a price band of Rs 265 to Rs 274 per Equity Share for its IPO opening on December 16.  Bids can be made for a minimum of 54 Equity Shares and in multiples of 54 equity shares thereafter. The three-day initial public offering (IPO) will conclude on December 20. The bidding for anchor ....

Satish Waman Wagh , Supriya Lifescience , Supriya Lifescience Limited , Equity Share , Satish Waman , Business News , Stock Markets ,

Supriya Lifescience IPO to open on Dec 16; sets price band at Rs 265-274/share - Jammu Kashmir Latest News | Tourism

New Delhi, Dec 13: Supriya Lifescience Ltd has fixed a price band of Rs 265-274 apiece for its Rs 700-crore initial share-sale, which will open for public subscription on December 16. The three-day initial public offering (IPO) will conclude on December 20. The bidding for anchor investors will open on December 15, according to the company. The company has cut the OFS (offer-for-sale) size to Rs 500 crore, from Rs 1,000 crore earlier. The IPO comprises fresh issue of equity […] ....

New Delhi , Satish Waman Wagh , Supriya Lifescience , Supriya Lifescience Ltd , Satish Waman , Axis Capital ,

Glenmark arm, Emcure, 3 other pharma companies line up Rs 7,000-crore IPOs

Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based bulk drugs firm Supriya Lifesciences, drug formulations firm Windlass Biotech, Bain Capital-backed Emcure Pharma and CX Partners-funded Veeda Clinical Research. According to investment-bankers, they are planning to mop up over Rs 7,000 crore in primary share sales. ....

United Kingdom , Supriya Lifesciences , Satish Mehta , Glenmark Lifesciences , Emcure Pharma , Satish Waman Wagh , Ajanta Pharma , Deepak Jasani , Aurobindo Pharma , Vinod Nair , Veeda Clinical Research , Bain Emcure Pharmaceuticals , Cx Veeda Clinical Research , Glenmark Pharmaceuticals , Geojit Financial Services , Windlass Biotech , Bain Capital Backed Emcure Pharma , Veeda Clinical , Arti Pharama , Ipca Labs , Gland Pharma , China Plus One , Bain Capital Backed Emcure Pharmaceuticals , Satish Waman , Initial Public Offering , Harma Ipo ,